367 related articles for article (PubMed ID: 11481279)
1. Normalization of retinal vascular permeability in experimental diabetes with genistein.
Nakajima M; Cooney MJ; Tu AH; Chang KY; Cao J; Ando A; An GJ; Melia M; de Juan E
Invest Ophthalmol Vis Sci; 2001 Aug; 42(9):2110-4. PubMed ID: 11481279
[TBL] [Abstract][Full Text] [Related]
2. VEGF-initiated blood-retinal barrier breakdown in early diabetes.
Qaum T; Xu Q; Joussen AM; Clemens MW; Qin W; Miyamoto K; Hassessian H; Wiegand SJ; Rudge J; Yancopoulos GD; Adamis AP
Invest Ophthalmol Vis Sci; 2001 Sep; 42(10):2408-13. PubMed ID: 11527957
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of vitreoretinal VEGF elevation and blood-retinal barrier breakdown in streptozotocin-induced diabetic rats by brimonidine.
Kusari J; Zhou SX; Padillo E; Clarke KG; Gil DW
Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):1044-51. PubMed ID: 19710406
[TBL] [Abstract][Full Text] [Related]
4. Reduction of retinal albumin leakage by the antioxidant calcium dobesilate in streptozotocin-diabetic rats.
Rota R; Chiavaroli C; Garay RP; Hannaert P
Eur J Pharmacol; 2004 Jul; 495(2-3):217-24. PubMed ID: 15249173
[TBL] [Abstract][Full Text] [Related]
5. Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic rats.
Kusari J; Zhou S; Padillo E; Clarke KG; Gil DW
Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):5152-9. PubMed ID: 17962468
[TBL] [Abstract][Full Text] [Related]
6. Effects of peroxisome proliferator-activated receptor gamma and its ligand on blood-retinal barrier in a streptozotocin-induced diabetic model.
Muranaka K; Yanagi Y; Tamaki Y; Usui T; Kubota N; Iriyama A; Terauchi Y; Kadowaki T; Araie M
Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4547-52. PubMed ID: 17003451
[TBL] [Abstract][Full Text] [Related]
7. Glial reactivity, an early feature of diabetic retinopathy.
Rungger-Brändle E; Dosso AA; Leuenberger PM
Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1971-80. PubMed ID: 10845624
[TBL] [Abstract][Full Text] [Related]
8. Baicalein reduces inflammatory process in a rodent model of diabetic retinopathy.
Yang LP; Sun HL; Wu LM; Guo XJ; Dou HL; Tso MO; Zhao L; Li SM
Invest Ophthalmol Vis Sci; 2009 May; 50(5):2319-27. PubMed ID: 19011009
[TBL] [Abstract][Full Text] [Related]
9. PKC-beta inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats.
Nonaka A; Kiryu J; Tsujikawa A; Yamashiro K; Miyamoto K; Nishiwaki H; Honda Y; Ogura Y
Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2702-6. PubMed ID: 10937586
[TBL] [Abstract][Full Text] [Related]
10. Aldose reductase inhibitor fidarestat attenuates leukocyte-endothelial interactions in experimental diabetic rat retina in vivo.
Hattori T; Matsubara A; Taniguchi K; Ogura Y
Curr Eye Res; 2010 Feb; 35(2):146-54. PubMed ID: 20136425
[TBL] [Abstract][Full Text] [Related]
11. Role of interleukin-1beta in the development of retinopathy in rats: effect of antioxidants.
Kowluru RA; Odenbach S
Invest Ophthalmol Vis Sci; 2004 Nov; 45(11):4161-6. PubMed ID: 15505070
[TBL] [Abstract][Full Text] [Related]
12. VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability.
Harhaj NS; Felinski EA; Wolpert EB; Sundstrom JM; Gardner TW; Antonetti DA
Invest Ophthalmol Vis Sci; 2006 Nov; 47(11):5106-15. PubMed ID: 17065532
[TBL] [Abstract][Full Text] [Related]
13. Endothelial F-actin cytoskeleton in the retinal vasculature of normal and diabetic rats.
Yu PK; Yu DY; Cringle SJ; Su EN
Curr Eye Res; 2005 Apr; 30(4):279-90. PubMed ID: 16020258
[TBL] [Abstract][Full Text] [Related]
14. Calcium dobesilate attenuates vascular injury and the progression of diabetic retinopathy in streptozotocin-induced diabetic rats.
Padilla E; Ganado P; Sanz M; Zeini M; Ruiz E; Triviño A; Ramírez AI; Salazar JJ; Ramírez JM; Rojas B; Hoz Rd; Tejerina T
Diabetes Metab Res Rev; 2005; 21(2):132-42. PubMed ID: 15386814
[TBL] [Abstract][Full Text] [Related]
15. Systemic and periocular deliveries of plasminogen kringle 5 reduce vascular leakage in rat models of oxygen-induced retinopathy and diabetes.
Zhang SX; Sima J; Wang JJ; Shao C; Fant J; Ma JX
Curr Eye Res; 2005 Aug; 30(8):681-9. PubMed ID: 16109649
[TBL] [Abstract][Full Text] [Related]
16. Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy.
Leal EC; Manivannan A; Hosoya K; Terasaki T; Cunha-Vaz J; Ambrósio AF; Forrester JV
Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):5257-65. PubMed ID: 17962481
[TBL] [Abstract][Full Text] [Related]
17. Specific retinal diacylglycerol and protein kinase C beta isoform modulation mimics abnormal retinal hemodynamics in diabetic rats.
Bursell SE; Takagi C; Clermont AC; Takagi H; Mori F; Ishii H; King GL
Invest Ophthalmol Vis Sci; 1997 Dec; 38(13):2711-20. PubMed ID: 9418723
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor in diabetes induced early retinal abnormalities.
Cukiernik M; Hileeto D; Evans T; Mukherjee S; Downey D; Chakrabarti S
Diabetes Res Clin Pract; 2004 Sep; 65(3):197-208. PubMed ID: 15331199
[TBL] [Abstract][Full Text] [Related]
19. A novel nonradioactive method to evaluate vascular barrier breakdown and leakage.
Trichonas G; Manola A; Morizane Y; Thanos A; Koufomichali X; Papakostas TD; Montezuma S; Young L; Miller JW; Gragoudas E; Vavvas D
Invest Ophthalmol Vis Sci; 2010 Mar; 51(3):1677-82. PubMed ID: 19875655
[TBL] [Abstract][Full Text] [Related]
20. Altered expression of retinal occludin and glial fibrillary acidic protein in experimental diabetes. The Penn State Retina Research Group.
Barber AJ; Antonetti DA; Gardner TW
Invest Ophthalmol Vis Sci; 2000 Oct; 41(11):3561-8. PubMed ID: 11006253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
